FLAURA2: Frontline osimertinib plus chemotherapy significantly improves OS in EGFR-mutated advanced NSCLC

ESMO 2025

Lung, Respiratory and Thoracic Cancer

FLAURA2 demonstrates OS advantage of osimertinib plus chemotherapy across prognostic groups in EGFR-mutated NSCLC

ELCC 2025

Lung, Respiratory and Thoracic Cancer

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

Lung, Respiratory and Thoracic Cancer

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)

Lung Cancer (Auckl)

Luo FX, Arter Z, Ou SI, Nagasaka M

doi: 10.2147/LCTT.S520833

Lung, Respiratory and Thoracic Cancer

CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression

Clin Lung Cancer

Wong WKY, Mok KKS, Tsui GPC, Chen OH, Loong HHF, Chan LL, Yan K, Mo F, Lee KWC, Lam KC, Mok FST, Johnson D, Chen ACC, Lam B, Lee M, Mok TSK, Li MSC

doi: 10.1016/j.cllc.2025.01.007

ELCC 2025

Lung, Respiratory and Thoracic Cancer

LAURA: Improved trend for OS benefit with osimertinib versus placebo in patients with unresectable stage III EGFR-mutant NSCLC

ELCC 2025

Lung, Respiratory and Thoracic Cancer

SAVANNAH: Savolitinib plus osimertinib shows high response rates in EGFR-mutant NSCLC with MET overexpression and/or amplification post-osimertinib

CHICAGO 2025

Breast Cancer

INAVO120: Inavolisib significantly improves OS when added to palbociclib and fulvestrant in patients with PIK3CA-mutated HR-positive, HER2-negative endocrine-resistant advanced breast cancer

WCLC 2025

Lung, Respiratory and Thoracic Cancer

EMPOWER-Lung 3: Cemiplimab plus chemotherapy provide sustained survival benefits in patients with advanced NSCLC

Lung, Respiratory and Thoracic Cancer

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset

Lung Cancer

Cho BC, Hayashi H, Lee JS, Lee SH, Danchaivijitr P, Cheng Y, Liu B, Alip A, Xiong H, How SH, Chang GC, Yang JC, Yoshioka H, Nahit Şendur MA, Prabhash K, Azuma K, Lee YG, Lin CC, Matsumoto S, Sunpaweravong P, Xia Y, Martinez M, Bauml JM, Sethi S, Lu S

doi: 10.1016/j.lungcan.2025.108496

Related content

FLAURA2 demonstrates OS advantage of osimertinib plus chemotherapy across prognostic groups in EGFR-mutated NSCLC

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)

CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression

LAURA: Improved trend for OS benefit with osimertinib versus placebo in patients with unresectable stage III EGFR-mutant NSCLC

SAVANNAH: Savolitinib plus osimertinib shows high response rates in EGFR-mutant NSCLC with MET overexpression and/or amplification post-osimertinib

INAVO120: Inavolisib significantly improves OS when added to palbociclib and fulvestrant in patients with PIK3CA-mutated HR-positive, HER2-negative endocrine-resistant advanced breast cancer

EMPOWER-Lung 3: Cemiplimab plus chemotherapy provide sustained survival benefits in patients with advanced NSCLC

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset